Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Nancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
British Journal of Haematology
|
June 26, 2014
Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system
Angela M B Collie, Jörk Nölling, Kiran M Divakar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
Luis Fayad, Fritz Offner, Mitchell R Smith, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
Anjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
Charles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Blood Advances
|
July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncology
Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Hematology (Amsterdam, Netherlands)
|
January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology
|
July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
November 22, 2016
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Nancy L Bartlett, Mitchell R Smith, Tanya Siddiqi, et al.
British Journal of Haematology
|
June 26, 2014
Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system
Angela M B Collie, Jörk Nölling, Kiran M Divakar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
Luis Fayad, Fritz Offner, Mitchell R Smith, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study
Anjali Advani, Bertrand Coiffier, Myron S Czuczman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
Charles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Blood Advances
|
July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2007
Multiple myeloma. Clinical practice guidelines in oncology
Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Hematology (Amsterdam, Netherlands)
|
January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology
|
July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Page
of 13